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Background: Class Ic agents are effective in the treatment of various atrial tachyarrhythmias. However, they are known to cause rate related 
QRS widening which can lead to life threatening arrhythmias. Prior studies showed that the presence of structural heart disease is a risk factor for 
rate related QRS widening. Current guidelines do not provide guidance on whether exercise ECG testing should be done routinely or only in select 
patients.
methods: We included all patients who were initiated on class Ic anti-arrhythmic agents and had exercise ECG performed between June 2009 and 
June 2013. Our current practice is to perform a treadmill ECG on all patients who are on a daily dose of at least 100mg of flecainide or 300 mg of 
propafenone. Symptom limited treadmill ECG was performed to detect significant QRS widening at peak exercise(defined as an increase of >25% of 
baseline QRS).
results: Patient and exercise test characteristics(n=57) are displayed in table 1. All patients were screened for structural heart disease prior to 
being initiated on a class Ic agents. Significant QRS widening and atrial tachycardia occurred in a single patient which terminated with cessation of 
exercise. This patient had a history of tachycardia mediated cardiomyopathy with normalization of ejection fraction three years prior to being placed 
on flecainide.
conclusions: In patients with no structural heart disease, routine exercise testing for detecting QRS widening is not warranted.
Table 1
n=57
Age 60+/-12.8 yrs
Body mass index
Female sex
31.5+/-7
33(57.9%)
Indication
Atrial fibrillation
Atrial tachycardia
Others
50(87.7%)
6(10.5%)
1(1.8%)
Class Ic agent used
Flecainide
Propafenone
47(82.5%)
10(17.5%)
Concomitant AV nodal blockers
Beta blockers
Calcium channel blockers
Digoxin
19(33.3%)
33(57.9%)
9(15.8%)
Mean daily dose of flecainide 204+/-55 mg
Mean daily dose of propafenone 590+/-240 mg
Peak heart rate 134+/- 30.5 bpm
METS achieved 6.2+/-2.6
